Medicus Pharma Seeks Orphan Drug Designation for SkinJect in Rare Gorlin Syndrome
核心洞察
Medicus Pharma (搜索) has submitted an orphan drug designation application to the FDA for SkinJect (搜索), a doxorubicin-containing microneedle array therapy for treating basal cell carcinoma (搜索) in Gorlin Syndrome (搜索) patients.
Gorlin Syndrome (搜索) affects approximately 11,000 patients in the United States and can cause patients to develop dozens to over 1,000 basal cell carcinomas throughout their lifetime, often beginning in childhood.
SkinJect (搜索) delivers doxorubicin directly into tumor tissue through a dissolvable microneedle array, providing high local drug concentrations while minimizing systemic exposure.
Medicus Pharma (搜索) Ltd. (NASDAQ: MDCX) announced the submission of an Orphan Drug Designation application to the U.S. Food and Drug Administration for SkinJect (搜索) (D-MNA) for treating basal cell carcinoma (搜索) in patients with Gorlin Syndrome (搜索), a rare genetic disorder characterized by multiple, recurrent skin cancers. The submission represents a strategic expansion into a high unmet need orphan indication where current treatment options are severely limited.
Addressing Critical Unmet Medical Need
Gorlin Syndrome (搜索), also known as nevoid basal cell carcinoma syndrome (搜索), is a rare inherited condition driven primarily by mutations in the PTCH1 (搜索) gene, leading to dysregulation of the Hedgehog signaling pathway (搜索) and early, recurrent tumor formation. The disease affects an estimated 11,000 patients in the United States, well below the 200,000 threshold required for orphan designation.
Patients with this condition face a devastating disease burden, potentially developing dozens to over 1,000 basal cell carcinomas over their lifetime, often beginning in childhood. This requires repeated surgical interventions that can result in significant physical and psychological burden, including cumulative morbidity and disfigurement.
Currently, there are no FDA-approved therapies specifically for basal cell carcinoma (搜索) in Gorlin Syndrome (搜索). Treatment relies heavily on surgical excision or Mohs surgery, while systemic therapies such as Hedgehog inhibitors are limited by tolerability issues and recurrence upon discontinuation.
Innovative Localized Treatment Approach
SkinJect (搜索) (D-MNA) is a doxorubicin-containing dissolvable microneedle array designed for direct intradermal delivery into basal cell carcinoma (搜索) lesions. The therapy offers several key advantages for Gorlin Syndrome (搜索) patients:
The microneedle array penetrates the skin and dissolves in situ, releasing doxorubicin locally to enable both direct cytotoxic tumor cell killing and induction of immunogenic cell death with local immune activation. This localized drug delivery approach achieves high concentrations directly in tumor tissue while maintaining minimal systemic exposure.
The minimally invasive, lesion-directed treatment is designed for repeat use across multiple lesions over time, making it particularly well-suited for Gorlin Syndrome (搜索) patients who require ongoing management of numerous tumors throughout their lives.
Clinical Evidence and Safety Profile
SkinJect (搜索) has been evaluated in Phase 1 and Phase 2 clinical studies in patients with basal cell carcinoma (搜索), demonstrating a favorable safety profile with adverse events primarily limited to the treatment site. The studies reported no serious adverse events or dose limiting toxicities, along with evidence of clinical clearance and histological complete responses in treated lesions.
While these studies were conducted in the broader basal cell carcinoma (搜索) population, Medicus believes the shared tumor biology between sporadic and Gorlin-associated basal cell carcinoma provides a strong rationale for expansion into this orphan indication.
Regulatory and Strategic Advantages
If granted, Orphan Drug Designation would provide significant benefits including seven years of U.S. market exclusivity upon approval, potential eligibility for tax credits and fee waivers, and enhanced regulatory interaction with the FDA.
The orphan drug designation submission strengthens Medicus' broader SkinJect (搜索) strategy by expanding into a regulatory-favorable orphan indication, positioning SkinJect as a repeatable, non-surgical platform therapy, and enhancing the program's partnering and out-licensing attractiveness.
The company has also established strategic collaborations to support patient access, including a partnership with the Gorlin Syndrome Alliance (搜索) to advance compassionate access through an Expanded Access IND program for patients with multiple or inoperable basal cell carcinomas.